All In Biotech

Drug Trial Radar · NCT05011019

A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis

Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis (Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors)

Last checked: Nov 19, 2026Latest source record: Mar 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

22

Actual

Start

Sep 7, 2021

Primary completion

Feb 2, 2024

Study completion Feb 2, 2024

Sponsor

Sponsor type
Industry
First posted
Aug 18, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

AL2846 is a multi-target receptor tyrosine kinase inhibitor. The purpose of this study is to evaluate the safety and efficacy of AL2846 capsules in Chinese patients with type I neurofibromatosis (NF1) (neurofibromas and malignant peripheral nerve sheath tumors).

Conditions

  • Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors

Interventions

  • AL2846 capsulesDrug

    AL2846 is a multi-target receptor tyrosine kinase inhibitor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse event rateTime frame: :Baseline up to 96 weeks
  2. objective response rate (ORR)Time frame: Baseline up to 96weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Ninth People's Hospital, School of Medicine, Shanghai JiaoTong University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.